• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

揭示血糖变异性的范围:对FreeStyle Libre监测数据的全新视角。

Unveiling the Spectrum of Glucose Variability: A Novel Perspective on FreeStyle Libre Monitoring Data.

作者信息

Heald Adrian H, Stedman Mike, Warner-Levy John, Belston Lleyton, Paisley Angela, Jotic Aleksandra, Lalic Nebojsa, Gibson Martin, Habte-Asres Hellena H, Whyte Martin, Forbes Angus

机构信息

The School of Medicine and Manchester Academic Health Sciences Centre, Manchester University, Manchester, UK.

Department of Endocrinology and Diabetes, Salford Royal Hospital, Salford, UK.

出版信息

Diabetes Ther. 2024 Dec;15(12):2475-2487. doi: 10.1007/s13300-024-01647-x. Epub 2024 Oct 23.

DOI:10.1007/s13300-024-01647-x
PMID:39443334
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11561226/
Abstract

INTRODUCTION

Since the introduction of insulin therapy, it has become apparent that type 1 diabetes (T1D) is accompanied by long-term microvascular and macrovascular complications. In the context of the many benefits of continuous glucose monitoring (CGM), there remain opportunities to study the large amount of data now available in order to maximise its potential in the endeavour to reduce the occurrence of diabetes tissue complications in the longer term.

METHODS

Continuous glucose monitoring values were downloaded for 89 type 1 diabetes mellitus (T1D) individuals for up to 18 months from 2021 to 2023. Data for patient demographics was also taken from the patient record which included Sex, Date of Birth, and Date of Diagnosis. The recorded laboratory glycated haemoglobin (HbA1c) test results were also recorded. The glucose management index (GMI) was calculated from average glucose readings for 18 months using the formula GMI (%) = (0.82 - (Average glucose/100)). This was then adjusted to give GMI (mmol/mol) = 10.929 * (GMI (%) - 2.15). Average Glucose Fluctuation (AGF) was calculated by adding up the total absolute change value between all recorded results over 18 months and dividing by the number of results minus one. The % Above Critical Threshold (ACT) was calculated by summing the total number of occurrences for each result value. A cumulative 95% limit was then applied to identify the glucose value that only 5% of results exceeded in the overall population. Using this value, we estimated the percentage of total tests that were above the Critical Threshold (ACT).

RESULTS

The mean age of the participants was 42.6 years, and the mean duration of T1D was 18.4 years. A total of 3.22 million readings were analysed, yielding an average blood glucose level of 10.3 mmol/l and a GMI of 57.2 mmol/mol. There was a strong correlation between GMI and measured HbA1c (r = 0.82). However, there were patients who had an above-critical threshold (ACT) of 4-10% at a GMI of 60 mmol/mol or less. The percentage average value at the time of day (%AVTD) was applied to all blood glucose readings at each 15-min interval throughout the day, averaged over 18 months. The %AVTD of GMI (overall average 57.2 mmol/mol) increased after midday, dipped at 18:00, and peaked at 22:00. The %AVTD of AGF (overall average 0.60 mmol/l) showed higher change rates after 09:00 declining at the end of the day. The %AVTD of ACT peaked at 22:00, with those having the highest %ACT showing an additional peak at 15:00.

CONCLUSIONS

We have shown here that the percentage glucose results above 18 mmol/l (top 5% of distribution) increased exponentially above 54 mmol/mol HbA1c. The %AVTD is introduced as a useful measure. Our data indicate that over the 24-h period, improvement in metabolic control could be focussed on the afternoon and evening, when there are higher-than-average levels of GMI, a higher-than-average degree of glucose change, and higher-than-average risks of being above the critical threshold. In conclusion, a measure of glycaemic variation based on the amplitude of glucose change to a population mean could be used to provide valuable clinical insights into glucose change over a 24-h period.

摘要

引言

自胰岛素疗法问世以来,1型糖尿病(T1D)会伴随长期微血管和大血管并发症这一点已变得很明显。在连续血糖监测(CGM)有诸多益处的背景下,仍有机会研究现有的大量数据,以便在长期努力降低糖尿病组织并发症发生率方面最大限度地发挥其潜力。

方法

从2021年到2023年,下载了89名1型糖尿病(T1D)患者长达18个月的连续血糖监测值。患者人口统计学数据也取自患者记录,包括性别、出生日期和诊断日期。还记录了实验室糖化血红蛋白(HbA1c)检测结果。血糖管理指数(GMI)根据18个月的平均血糖读数,使用公式GMI(%)=(0.82 - (平均血糖/100))计算得出。然后进行调整,得出GMI(mmol/mol)= 10.929×(GMI(%) - 2.15)。平均血糖波动(AGF)通过将18个月内所有记录结果之间的总绝对变化值相加,再除以结果数量减1来计算。高于临界阈值的百分比(ACT)通过对每个结果值的出现总数求和来计算。然后应用累积95%限值来确定总体中仅5%的结果超过的血糖值。利用该值,我们估计了高于临界阈值(ACT)的总检测的百分比。

结果

参与者的平均年龄为42.6岁,T1D的平均病程为18.4年。共分析了322万个读数,得出平均血糖水平为10.3 mmol/l,GMI为57.2 mmol/mol。GMI与测得的HbA1c之间存在强相关性(r = 0.82)。然而,有患者在GMI为60 mmol/mol或更低时,高于临界阈值(ACT)为4% - 10%。将一天中各时间点的百分比平均值(%AVTD)应用于全天每个15分钟间隔的所有血糖读数,并在18个月内进行平均。GMI的%AVTD(总体平均值57.2 mmol/mol)在中午过后升高,18:00下降,22:00达到峰值。AGF的%AVTD(总体平均值0.60 mmol/l)在09:00后显示出更高的变化率,在一天结束时下降。ACT的%AVTD在22:00达到峰值,ACT最高的那些人在15:00还出现一个额外峰值。

结论

我们在此表明,血糖结果高于18 mmol/l(分布的前5%)的百分比在HbA1c高于54 mmol/mol时呈指数增长。引入%AVTD作为一种有用的测量方法。我们的数据表明,在24小时期间,代谢控制的改善可以集中在下午和晚上,此时GMI水平高于平均水平,血糖变化程度高于平均水平,且高于临界阈值的风险高于平均水平。总之,基于血糖变化幅度相对于总体均值的血糖变异性测量方法可用于提供有关24小时期间血糖变化的有价值的临床见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/971c/11561226/43b6a5382e2f/13300_2024_1647_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/971c/11561226/9fa7cc023488/13300_2024_1647_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/971c/11561226/610cdf7e7d79/13300_2024_1647_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/971c/11561226/803f5d8d1e5b/13300_2024_1647_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/971c/11561226/43b6a5382e2f/13300_2024_1647_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/971c/11561226/9fa7cc023488/13300_2024_1647_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/971c/11561226/610cdf7e7d79/13300_2024_1647_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/971c/11561226/803f5d8d1e5b/13300_2024_1647_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/971c/11561226/43b6a5382e2f/13300_2024_1647_Fig4_HTML.jpg

相似文献

1
Unveiling the Spectrum of Glucose Variability: A Novel Perspective on FreeStyle Libre Monitoring Data.揭示血糖变异性的范围:对FreeStyle Libre监测数据的全新视角。
Diabetes Ther. 2024 Dec;15(12):2475-2487. doi: 10.1007/s13300-024-01647-x. Epub 2024 Oct 23.
2
The Relation of Diabetes Complications to a New Interpretation of Glycaemic Variability from Continuous Glucose Monitoring in People with Type 1 Diabetes.1型糖尿病患者糖尿病并发症与连续血糖监测对血糖变异性的新解读之间的关系
Diabetes Ther. 2024 Dec;15(12):2489-2498. doi: 10.1007/s13300-024-01648-w. Epub 2024 Oct 23.
3
4
Performance of the Glucose Management Indicator (GMI) in Type 2 Diabetes.2 型糖尿病患者的血糖管理指标(GMI)表现。
Clin Chem. 2023 Apr 3;69(4):422-428. doi: 10.1093/clinchem/hvac210.
5
Continuous glucose monitoring with FreeStyle Libre PRO sensor in patients with type 2 diabetes and end-stage renal failure on haemoDIALysis (FSLPRO-DIAL pilot study).使用FreeStyle Libre PRO传感器对接受血液透析的2型糖尿病和终末期肾衰竭患者进行连续血糖监测(FSLPRO-DIAL试点研究)。
Acta Diabetol. 2024 Dec;61(12):1537-1541. doi: 10.1007/s00592-024-02323-z. Epub 2024 Jun 26.
6
Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin.了解血糖管理指标与糖化血红蛋白之间差异的临床意义。
Diabetes Obes Metab. 2022 Apr;24(4):599-608. doi: 10.1111/dom.14638. Epub 2022 Feb 8.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
The Discrepancy Between Hemoglobin A1c and Glucose Management Indicators in 26 Patients Treated With Continuous Glucose Monitoring in an Internal Medicine Residency Clinic.内科住院医师诊所中26例接受持续血糖监测治疗患者的糖化血红蛋白与血糖管理指标之间的差异
Cureus. 2024 Mar 23;16(3):e56768. doi: 10.7759/cureus.56768. eCollection 2024 Mar.
9
The potential of glucose management indicator for the estimation of glucose disposal rate in people with type 1 diabetes.葡萄糖管理指标在估计 1 型糖尿病患者葡萄糖处置率中的潜力。
Nutr Metab Cardiovasc Dis. 2024 Oct;34(10):2344-2352. doi: 10.1016/j.numecd.2024.06.013. Epub 2024 Jun 21.
10
Discordance Between Glycated Hemoglobin A1c and the Glucose Management Indicator in People With Diabetes and Chronic Kidney Disease.糖化血红蛋白 A1c 与慢性肾脏病糖尿病患者血糖管理指标的不相符。
J Diabetes Sci Technol. 2023 Nov;17(6):1553-1562. doi: 10.1177/19322968221092050. Epub 2022 Apr 25.

引用本文的文献

1
Consistency of the personalized glycated haemoglobin (pHbA1c) methodology over time in people with type 1 diabetes (T1D) using continuous glucose monitoring.使用连续血糖监测的1型糖尿病(T1D)患者中个性化糖化血红蛋白(pHbA1c)方法随时间的一致性。
Diabet Med. 2025 Apr;42(4):e15520. doi: 10.1111/dme.15520. Epub 2025 Feb 3.

本文引用的文献

1
Hypoglycemia and glycemic variability of people with type 1 diabetes with lower and higher physical activity loads in free-living conditions using continuous subcutaneous insulin infusion with predictive low-glucose suspend system.在自由生活条件下,使用具有预测性低血糖暂停系统的持续皮下胰岛素输注,对身体活动负荷较低和较高的1型糖尿病患者的低血糖和血糖变异性进行研究。
BMJ Open Diabetes Res Care. 2023 Mar;11(2). doi: 10.1136/bmjdrc-2022-003082.
2
Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes.1 型糖尿病的间歇性扫描连续血糖监测。
N Engl J Med. 2022 Oct 20;387(16):1477-1487. doi: 10.1056/NEJMoa2205650. Epub 2022 Oct 5.
3
Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis.
速效门冬胰岛素与门冬胰岛素在胰岛素泵治疗 1 型糖尿病中的比较:一项荟萃分析。
Diabetes Metab J. 2023 Jan;47(1):72-81. doi: 10.4093/dmj.2022.0035. Epub 2022 Jun 24.
4
Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin.了解血糖管理指标与糖化血红蛋白之间差异的临床意义。
Diabetes Obes Metab. 2022 Apr;24(4):599-608. doi: 10.1111/dom.14638. Epub 2022 Feb 8.
5
The Relationship Between CGM-Derived Metrics, A1C, and Risk of Hypoglycemia in Older Adults With Type 1 Diabetes.1型糖尿病老年患者中持续葡萄糖监测衍生指标、糖化血红蛋白与低血糖风险之间的关系
Diabetes Care. 2020 Oct;43(10):2349-2354. doi: 10.2337/dc20-0016. Epub 2020 May 27.
6
Meal timing, meal frequency, and breakfast skipping in adult individuals with type 1 diabetes - associations with glycaemic control.1 型糖尿病成人的进餐时间、进餐频率和不吃早餐与血糖控制的关系。
Sci Rep. 2019 Dec 27;9(1):20063. doi: 10.1038/s41598-019-56541-5.
7
Critical Reappraisal of the Time-in-Range: Alternative or Useful Addition to Glycated Hemoglobin?时间范围内的再评估:糖化血红蛋白的替代指标还是有用的补充?
J Diabetes Sci Technol. 2020 Sep;14(5):922-927. doi: 10.1177/1932296819883885. Epub 2019 Nov 1.
8
Distinct Patterns of Daily Glucose Variability by Pubertal Status in Youth With Type 1 Diabetes.青春期状态对 1 型糖尿病青少年日间血糖变异性的影响模式不同。
Diabetes Care. 2020 Jan;43(1):22-28. doi: 10.2337/dc19-0083. Epub 2019 Jul 15.
9
Glucose Management Indicator (GMI): Insights and Validation Using Guardian 3 and Navigator 2 Sensor Data.血糖管理指标(GMI):使用Guardian 3和Navigator 2传感器数据的见解与验证
Diabetes Care. 2019 Apr;42(4):e60-e61. doi: 10.2337/dc18-2479. Epub 2019 Feb 6.
10
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.验证时间在范围内作为糖尿病临床试验的结果测量。
Diabetes Care. 2019 Mar;42(3):400-405. doi: 10.2337/dc18-1444. Epub 2018 Oct 23.